DDInter383 DDInter1082
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Cinoxacin {u} (Compound) binds {v} (Gene) SLC22A6
Cinoxacin {u} (Compound) causes {v} (Side Effect) Somnolence
Cinoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idarubicin
Cinoxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Epirubicin
Cinoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Cinoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sevelamer
Cinoxacin {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Cinoxacin {u} may lead to a major life threatening interaction when taken with {v} Betamethasone
Cinoxacin (Compound) binds SLC22A6 (Gene)
Cinoxacin (Compound) causes Somnolence (Side Effect)
Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Cinoxacin may cause a minor interaction that can limit clinical effects when taken with Epirubicin
Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Sevelamer
Cinoxacin may lead to a major life threatening interaction when taken with Deflazacort
Cinoxacin may lead to a major life threatening interaction when taken with Betamethasone